CATALOGO DEI PRODOTTI DELLA RICERCA

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.395
EU - Europa 9.953
AS - Asia 8.093
SA - Sud America 1.035
AF - Africa 176
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 14
Totale 29.681
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.242
RU - Federazione Russa 3.701
SG - Singapore 3.159
CN - Cina 2.746
GB - Regno Unito 2.142
IT - Italia 873
BR - Brasile 790
VN - Vietnam 668
HK - Hong Kong 644
DE - Germania 619
FR - Francia 608
FI - Finlandia 540
IE - Irlanda 497
SE - Svezia 490
KR - Corea 269
IN - India 139
NL - Olanda 110
UA - Ucraina 104
AR - Argentina 87
CA - Canada 66
JP - Giappone 60
BD - Bangladesh 57
ID - Indonesia 55
TR - Turchia 52
PL - Polonia 49
ZA - Sudafrica 48
EC - Ecuador 47
MX - Messico 47
IQ - Iraq 45
ES - Italia 40
BE - Belgio 33
CH - Svizzera 28
AT - Austria 25
CO - Colombia 25
PK - Pakistan 25
MA - Marocco 23
VE - Venezuela 23
CL - Cile 22
NG - Nigeria 22
SA - Arabia Saudita 18
PY - Paraguay 17
UZ - Uzbekistan 16
IR - Iran 15
PH - Filippine 15
EU - Europa 14
NP - Nepal 14
CZ - Repubblica Ceca 13
LT - Lituania 13
TN - Tunisia 13
EG - Egitto 12
KE - Kenya 12
MY - Malesia 12
PE - Perù 12
AZ - Azerbaigian 11
TG - Togo 11
AU - Australia 10
AE - Emirati Arabi Uniti 9
TH - Thailandia 9
AL - Albania 8
BJ - Benin 8
CR - Costa Rica 8
LV - Lettonia 8
DZ - Algeria 7
OM - Oman 7
PT - Portogallo 7
BO - Bolivia 6
GR - Grecia 6
HN - Honduras 6
RS - Serbia 6
DK - Danimarca 5
DO - Repubblica Dominicana 5
IL - Israele 5
JM - Giamaica 5
JO - Giordania 5
AM - Armenia 4
KZ - Kazakistan 4
MK - Macedonia 4
NI - Nicaragua 4
NO - Norvegia 4
UY - Uruguay 4
BG - Bulgaria 3
CI - Costa d'Avorio 3
CM - Camerun 3
CY - Cipro 3
GA - Gabon 3
GE - Georgia 3
KG - Kirghizistan 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
RO - Romania 3
SI - Slovenia 3
SN - Senegal 3
SV - El Salvador 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
EE - Estonia 2
KH - Cambogia 2
LU - Lussemburgo 2
Totale 29.646
Salva come PNG Salva come JPEG
Città #
Southend 1.886
Singapore 1.583
Moscow 1.145
Chandler 1.084
San Jose 1.054
Woodbridge 955
Ashburn 915
Dallas 833
Hong Kong 636
Ann Arbor 620
Dublin 492
Beijing 470
Jacksonville 444
The Dalles 435
Houston 412
Verona 363
Jinan 247
Ho Chi Minh City 238
Lawrence 236
Princeton 236
New York 194
Wilmington 191
Nanjing 187
Munich 186
Los Angeles 172
Shenyang 157
Hanoi 155
Helsinki 131
Hebei 118
Redondo Beach 106
Tianjin 106
Buffalo 95
Changsha 79
Ningbo 77
São Paulo 74
Haikou 70
Milan 69
Santa Clara 69
Guangzhou 62
Council Bluffs 61
Zhengzhou 60
Nanchang 59
Hangzhou 57
Sindelfingen 54
Tokyo 54
Columbus 53
Jiaxing 49
London 49
Taizhou 47
Seoul 45
Frankfurt am Main 43
Turku 39
Orem 38
Taiyuan 38
Chennai 36
Seattle 35
Brussels 33
Fuzhou 30
Warsaw 30
Rio de Janeiro 29
Montreal 28
San Francisco 28
Amsterdam 26
Boardman 26
Brooklyn 26
Chicago 26
Johannesburg 26
Lanzhou 26
Norwalk 26
Denver 25
Rome 25
Falls Church 24
Redwood City 24
Dearborn 23
Lancaster 22
Abuja 21
Mexico City 21
Mumbai 21
Stockholm 21
Da Nang 20
Haiphong 20
Quito 20
Baghdad 19
Atlanta 18
Jakarta 18
Phoenix 18
Zurich 18
Hải Dương 17
Nuremberg 17
Belo Horizonte 16
Boston 16
Porto Alegre 16
Bologna 15
Meda 15
Biên Hòa 14
Curitiba 14
Madrid 14
Poplar 14
Shanghai 14
Tashkent 14
Totale 18.333
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 307
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 285
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 247
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 241
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 239
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 230
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 225
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 219
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 212
Le linee guida AIOM, ASCO e MASCC-ESMO sull'emesi da chemioterapia e radioterapia: considerazioni e approfondimenti. 210
Adenocarcinoma of the paraurethral glands: a case report 209
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 209
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 207
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 200
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 200
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 198
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 196
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis 196
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 196
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 194
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 194
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 189
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 188
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 187
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 187
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 186
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 186
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 185
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 184
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 184
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 181
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 179
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 179
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 177
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 177
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 176
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 175
The development of PARP as a successful target for cancer therapy 175
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 175
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 174
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 174
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 173
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 171
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 169
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients 165
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 164
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 164
Do immune checkpoint inhibitors need new studies methodology? 163
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 162
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 161
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 160
2-weekly docetaxel: issues for clinical practice. 159
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 159
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 157
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 157
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 154
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers 154
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 150
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 150
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 149
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 147
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 145
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 145
Acute emesis: Moderately emetogenic chemotherapy. 143
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 142
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 141
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 140
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 139
Clinical meta-analyses of targeted therapies in adenocarcinoma. 138
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 136
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 135
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 134
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 134
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 133
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 133
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 131
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 131
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 130
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 130
Physical activity and exercise in lung cancer care: will promises be fulfilled? 130
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 130
Adjuvant chemotherapy for bladder cancer: the chance for meta-aalyses comparison 128
Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era 127
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 126
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. 126
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 126
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 125
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 125
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 124
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 123
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 122
Clinical meta-analyses of targeted therapies in adenocarcinoma. 122
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 121
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 120
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 119
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 119
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences 118
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status 117
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 116
Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab 116
Totale 16.460
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.930
article - articoli 97.095
book - libri 502
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.333
Totale 205.860
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021195 0 0 0 0 0 0 0 0 0 19 153 23
2021/20221.660 104 543 11 157 43 30 27 99 67 41 136 402
2022/20233.118 270 268 318 585 272 753 32 191 288 19 88 34
2023/20241.541 77 112 118 155 220 225 41 191 32 70 229 71
2024/20254.445 234 266 173 799 134 157 160 215 751 326 329 901
2025/202612.055 961 701 925 1.991 3.120 766 1.218 676 1.045 652 0 0
Totale 29.924